Biosimilar Substitution Financial Risk in Buy-and-Bill
Biosimilar competition is collapsing reimbursement faster than practices can adjust.
Darius Okonkwo
Section
Drug Cost & Reimbursement
7 stories in Drug Cost & Reimbursement.
Drug Waste Billing Compliance in Infusion Reimbursement
Misclassifying vials costs practices through denials with no recovery path.
Renata Szymborska
Prior Authorization Failure as a Drug Cost Liability Event
Prior authorization denials in buy-and-bill infusion create unrecoverable financial losses.
Darius Okonkwo
Catastrophic Claim Concentration Risk in Small Infusion Groups
One denial on a five-figure drug claim can erase an entire month's margin for small infusion groups.
Renata Szymborska
Underpayment vs Denial Risk in Biologic Claims
Denial and underpayment require different strategies to protect biologic revenue.
Darius Okonkwo
J-Code Billing Errors That Trigger Biologic Denials
How to avoid the five most expensive J-code mistakes that tank biologic claims.
Jerome Castellano
Biologic Denial Financial Exposure Modeling
Infusion practices vastly underestimate denial costs by tracking only lost reimbursement.
Darius Okonkwo